Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Showcase Companies

Stockhouse is proud to showcase a portfolio of companies that we are watching closely. Learn more about these companies as part of your own investment research. Consider using the tools below to be first in line for important news and updates. view all showcase companies

MindBio Therapeutics Corp. C.MBIO

MindBio Therapeutics Corp is a pioneering clinical stage biotechnology company that specializes in developing psychedelic microdosing treatments for mental health conditions. MindBio has obtained government and regulatory approvals for at-home LSD microdosing in clinical trials, making it the only organization in the world to do so.

Latest News

MindBio Therapeutics Scientists Present Landmark Women's Health Trials. Company To Release Phase...

Accesswire

MindBio Is Exploring Dual Listing on A Senior Exchange with Multiple Phase 2B Clinical Trials...

Accesswire

MindBio Therapeutics Announces Landmark Women's Health CNS Drug Trials

Accesswire

MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational...

Accesswire

Lender Requests to Convert Loan to MindBio Shares

Accesswire

MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with...

Accesswire

MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled...

Accesswire

MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home...

Accesswire

MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial

Accesswire

MindBio Therapeutics Nears Completion of Landmark Phase 2a LSD Microdosing (MB22001) Clinical...

Accesswire

MindBio Therapeutics CEO Provides End of Year Video Update on Phase 2 Clinical Trials

Accesswire

MindBio Therapeutics Team Members Honoured with Industry Leading Awards

Accesswire

MindBio Therapeutics CEO Presents World First Phase 2B Take-Home Microdosing Clinical Trial in...

Accesswire

MindBio Therapeutics Begins Dosing MB22001 in World First Phase 2B Microdosing Clinical Trial In...

Accesswire

Mindbio Therapeutics Nominated for Company of the Year in Industry Awards

Accesswire

Dealroom for high-potential pre-IPO opportunities